POTELIGEO
Google image searchProduct monograph
Active ingredient
mogamulizumab, 4 MG/ML
DIN: 02527715
Dosage form(s): SOLUTION
Route(s) of administration: INTRAVENOUS
Description: SINGLE-USE VIAL
Schedule: Prescription / Schedule D
Company: KYOWA KIRIN, INC.
Date: 27-MAR-2024
ATC:
- L01 — ANTINEOPLASTIC AGENTS (ATC, ATC/DDD, )
- L01F — MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES (ATC, ATC/DDD)
- L01FX — Other monoclonal antibodies and antibody drug conjugates (ATC, ATC/DDD)
- L01FX09 — MOGAMULIZUMAB (ATC/DDD)
